XK469R in Treating Patients With Refractory Hematologic Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of XK469R in treating patients who have refractory
hematologic cancer. Drugs used in chemotherapy, such XK469R, work in different ways to stop
cancer cells from dividing so they stop growing or die